<DOC>
	<DOCNO>NCT02095574</DOCNO>
	<brief_summary>A pharmacokinetic study access body absorbs remove ABT-199 adult Non-Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>A Pharmacokinetic Study Access How Body Absorbs Removes ABT-199 Adults With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>1 . Subject must relapse refractory disease . 2 . Subject must histologically document diagnosis nonhodgkin 's lymphoma define Bcell neoplasm World Health Organization ( WHO ) classification scheme except noted exclusion criterion . 3 . Subject Eastern Cooperative Oncology Group ( ECOG ) performance score 02 . 4 . Subject adequate bone marrow ( independent growth factor support per local laboratory reference range ) . 5 . Subject adequate coagulation , renal hepatic function . 1 . Subject diagnose PostTransplant Lymphoproliferative Disease ( PTLD ) , Burkitt 's lymphoma , Burkittlike lymphoma , lymphoblastic lymphoma/leukemia , chronic lymphocytic leukemia ( CLL ) , mantle cell leukemia ( MCL ) , small lymphocytic lymphoma ( SLL ) . 2 . Subject undergone allogeneic stem cell transplant . 3 . Subject receive combination antiretroviral therapy human immunodeficiency virus ( HIV ) ( due potential drugdrug interaction , well potential increase risk opportunistic infection ) . 4 . Subject significant history renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , cardiovascular , hepatic disease within 6 month opinion Investigator would adversely affect his/her participation study . 5 . Subject active peptic ulcer disease hemorrhagic esophagitis/gastritis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>GDC-0199</keyword>
	<keyword>ADME</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>ABT-199</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
</DOC>